• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Viking Global Investors Lp bought $8,538,385 worth of shares (847,062 units at $10.08)

    11/4/22 6:17:12 PM ET
    $FLAC
    Business Services
    Finance
    Get the next $FLAC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    VIKING GLOBAL INVESTORS LP

    (Last) (First) (Middle)
    55 RAILROAD AVENUE

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Frazier Lifesciences Acquisition Corp [ FLAC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/02/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/02/2022 P 567,532 A $10.08 2,459,880 I See Explanation of Responses(1)(2)(4)
    Common Stock 11/02/2022 P 279,530 A $10.08 1,211,582 I See Explanation of Responses(1)(3)(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    VIKING GLOBAL INVESTORS LP

    (Last) (First) (Middle)
    55 RAILROAD AVENUE

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Viking Global Opportunities Illiquid Investments Sub-Master LP

    (Last) (First) (Middle)
    55 RAILROAD AVENUE

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Viking Global Opportunities Portfolio GP LLC

    (Last) (First) (Middle)
    55 RAILROAD AVENUE

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Viking Global Opportunities GP LLC

    (Last) (First) (Middle)
    55 RAILROAD AVENUE

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Viking Global Opportunities Parent GP LLC

    (Last) (First) (Middle)
    55 RAILROAD AVENUE

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    HALVORSEN OLE ANDREAS

    (Last) (First) (Middle)
    55 RAILROAD AVENUE

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Ott David C.

    (Last) (First) (Middle)
    55 RAILROAD AVENUE

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Shabet Rose Sharon

    (Last) (First) (Middle)
    55 RAILROAD AVENUE

    (Street)
    GREENWICH CT 06830

    (City) (State) (Zip)
    Explanation of Responses:
    1. Andreas Halvorsen, David C. Ott and Rose S. Shabet are Executive Committee members of certain management entities, including Viking Global Partners LLC, the general partner of Viking Global Investors LP ("VGI"), and Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), the sole member of Viking Global Opportunities GP LLC ("Opportunities GP"), which is the sole member of Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), which is the general partner of Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"). Opportunities Parent is also the sole member of Viking Global Opportunities Drawdown GP LLC ("VGOD GP"), which is the sole member of Viking Global Opportunities Drawdown Portfolio GP LLC ("VGOD Portfolio GP"), which is the general partner of Viking Global Opportunities Drawdown (Aggregator) LP ("VGOD"). VGI provides managerial services to various investment funds and vehicles, including VGOP and VGOD.
    2. These shares are held directly by VGOP. Because of the relationship between VGI, Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott, Ms. Shabet and VGOP, each of VGI, Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, Mr. Halvorsen, Mr. Ott and Ms. Shabet may be deemed to beneficially own the shares held directly by VGOP.
    3. These shares are held directly by VGOD. Because of the relationship between VGI, Opportunities Parent, Mr. Halvorsen, Mr. Ott, Ms. Shabet and VGOD, each of VGI, Opportunities Parent, Mr. Halvorsen, Mr. Ott and Ms. Shabet may be deemed to beneficially own the shares held directly by VGOD.
    4. VGI, Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, VGOP, Mr. Halvorsen, Mr. Ott and Ms. Shabet (collectively the "Reporting Persons") disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
    Remarks:
    (5) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. (6) Scott M. Hendler is signing on behalf of Mr. Halvorsen, Mr. Ott and Ms. Shabet, each individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to authorization and designation letters dated February 9, 2021, which were filed with the Securities and Exchange Commission on June 7, 2021.
    /s/ Scott M. Hendler signing on behalf of O. Andreas Halvorsen (5) (6) 11/04/2022
    /s/ Scott M. Hendler signing on behalf of David C. Ott (5) (6) 11/04/2022
    /s/ Scott M. Hendler signing on behalf of Rose S. Shabet (5) (6) 11/04/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FLAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLAC
    Leadership Updates

    Live Leadership Updates

    See more
    • Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

      FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he

      9/26/22 8:00:00 AM ET
      $ALPN
      $ANAB
      $FLAC
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Finance

    $FLAC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Frazier Lifesciences Acquisition Corporation

      15-12G - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)

      12/2/22 4:30:53 PM ET
      $FLAC
      Business Services
      Finance
    • Frazier Lifesciences Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)

      11/23/22 4:36:01 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 25-NSE filed by Frazier Lifesciences Acquisition Corporation

      25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      11/22/22 4:17:19 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      2/15/23 10:14:02 AM ET
      $FLAC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      12/1/22 4:51:17 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form SC 13D/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      11/25/22 1:43:14 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

      FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he

      9/26/22 8:00:00 AM ET
      $ALPN
      $ANAB
      $FLAC
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Finance
    • Frazier Healthcare Partners Announces Several Promotions on Life Sciences Team

      Frazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabral to Senior Associate. Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Frazier's public equity investment strategy. He is the co-portfolio manager for Frazier Life Sciences Public Fund, an $830 million long-only fund that invests in small- and mid-cap public biotech companies. He led Frazier's public investments in Trillium Therapeutics (NASDAQ:TRIL, pending acquisition by Pfizer))), Translate Bio (NASDAQ:TBIO, acquired

      10/28/21 8:00:00 AM ET
      $FLAC
      $ISEE
      $KRYS
      $RCKT
      Business Services
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Viking Global Investors Lp

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/25/22 1:35:02 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 4 filed by Topper David Joseph

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/23/22 4:31:11 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 4 filed by Bigham Michael

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/23/22 4:27:56 PM ET
      $FLAC
      Business Services
      Finance